Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251133741> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4251133741 endingPage "TPS3623" @default.
- W4251133741 startingPage "TPS3623" @default.
- W4251133741 abstract "TPS3623 Background: Immune checkpoint inhibitor (ICI) was reported to show durable responses in patients with MSI-H (Microsatellite Instability-High) metastatic colorectal cancer (mCRC). On the other hand, for patients with MSS (Microsatellite Stable) mCRC, ICI monotherapy achieved no response. Recently, WNT/β-catenin signaling has been reported to be involved in the elimination of tumor-infiltrating lymphocytes and the resistance of anti-PD-L1 antibodies. CRC is representative cancer with WNT/β-catenin pathway activation. Furthermore, STAT3 has also been reported to be a key driver of this immune evasion. Considering these rationales, the blocking of these signaling pathways with ICI may enhance antitumor immune response. Therefore, we initiated phase I/II study to assess efficacy and safety for the combination of BBI608, which blocks STAT3 and WNT/β-catenin signaling, with pembrolizumab in patients with mCRC. Methods: The eligibility criteria were patients with gastrointestinal cancer not responded to or intolerant of standard chemotherapies (SOC) for phase I part, and MSS mCRC refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, and anti-EGFR antibody (if wild-type RAS) for Cohort B in phase II part. For Cohort A, MSI-H mCRC refractory or intolerant to the SOC, irrespective of anti-EGFR antibody are investigated. Phase I part was designed to determine the recommended phase II dose in a “3+3” cohort-based dose escalation design of BBI608 (240mg BID every day on level 1 and 480mg BID every day on level 2) with pembrolizumab (200mg/body q3w). Primary endpoint of the phase II part is Immune-related objective response rate (irORR) determined by their Response Evaluation Criteria In Solid Tumors (irRECIST). A null hypothesis and alternative hypothesis for cohort B are irORR = 5% and 20%, respectively. Required sample size for Cohort B was 40 with a one-sided alpha of 5% and power of 90%. Required sample size for Cohort A (10 patients) was determined in an exploratory manner. We also investigate biomarker study using paired samples of both tumor biopsy and blood. The enrollment to phase I part began in November 2016. Clinical trial information: NCT02851004. Clinical trial information: NCT02851004." @default.
- W4251133741 created "2022-05-12" @default.
- W4251133741 creator A5000895933 @default.
- W4251133741 creator A5007693211 @default.
- W4251133741 creator A5009022286 @default.
- W4251133741 creator A5012914486 @default.
- W4251133741 creator A5019984630 @default.
- W4251133741 creator A5024904484 @default.
- W4251133741 creator A5033862426 @default.
- W4251133741 creator A5035370322 @default.
- W4251133741 creator A5037958902 @default.
- W4251133741 creator A5054182211 @default.
- W4251133741 creator A5054876338 @default.
- W4251133741 creator A5062104528 @default.
- W4251133741 creator A5062748030 @default.
- W4251133741 creator A5064941052 @default.
- W4251133741 creator A5073300663 @default.
- W4251133741 creator A5081842907 @default.
- W4251133741 creator A5089162253 @default.
- W4251133741 date "2017-05-20" @default.
- W4251133741 modified "2023-10-16" @default.
- W4251133741 title "Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503." @default.
- W4251133741 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps3623" @default.
- W4251133741 hasPublicationYear "2017" @default.
- W4251133741 type Work @default.
- W4251133741 citedByCount "2" @default.
- W4251133741 countsByYear W42511337412019 @default.
- W4251133741 countsByYear W42511337412022 @default.
- W4251133741 crossrefType "journal-article" @default.
- W4251133741 hasAuthorship W4251133741A5000895933 @default.
- W4251133741 hasAuthorship W4251133741A5007693211 @default.
- W4251133741 hasAuthorship W4251133741A5009022286 @default.
- W4251133741 hasAuthorship W4251133741A5012914486 @default.
- W4251133741 hasAuthorship W4251133741A5019984630 @default.
- W4251133741 hasAuthorship W4251133741A5024904484 @default.
- W4251133741 hasAuthorship W4251133741A5033862426 @default.
- W4251133741 hasAuthorship W4251133741A5035370322 @default.
- W4251133741 hasAuthorship W4251133741A5037958902 @default.
- W4251133741 hasAuthorship W4251133741A5054182211 @default.
- W4251133741 hasAuthorship W4251133741A5054876338 @default.
- W4251133741 hasAuthorship W4251133741A5062104528 @default.
- W4251133741 hasAuthorship W4251133741A5062748030 @default.
- W4251133741 hasAuthorship W4251133741A5064941052 @default.
- W4251133741 hasAuthorship W4251133741A5073300663 @default.
- W4251133741 hasAuthorship W4251133741A5081842907 @default.
- W4251133741 hasAuthorship W4251133741A5089162253 @default.
- W4251133741 hasConcept C121608353 @default.
- W4251133741 hasConcept C126322002 @default.
- W4251133741 hasConcept C137620995 @default.
- W4251133741 hasConcept C143998085 @default.
- W4251133741 hasConcept C203092338 @default.
- W4251133741 hasConcept C2777701055 @default.
- W4251133741 hasConcept C2780057760 @default.
- W4251133741 hasConcept C2780259306 @default.
- W4251133741 hasConcept C2780962732 @default.
- W4251133741 hasConcept C31760486 @default.
- W4251133741 hasConcept C502942594 @default.
- W4251133741 hasConcept C526805850 @default.
- W4251133741 hasConcept C535046627 @default.
- W4251133741 hasConcept C55493867 @default.
- W4251133741 hasConcept C62478195 @default.
- W4251133741 hasConcept C71924100 @default.
- W4251133741 hasConcept C86803240 @default.
- W4251133741 hasConceptScore W4251133741C121608353 @default.
- W4251133741 hasConceptScore W4251133741C126322002 @default.
- W4251133741 hasConceptScore W4251133741C137620995 @default.
- W4251133741 hasConceptScore W4251133741C143998085 @default.
- W4251133741 hasConceptScore W4251133741C203092338 @default.
- W4251133741 hasConceptScore W4251133741C2777701055 @default.
- W4251133741 hasConceptScore W4251133741C2780057760 @default.
- W4251133741 hasConceptScore W4251133741C2780259306 @default.
- W4251133741 hasConceptScore W4251133741C2780962732 @default.
- W4251133741 hasConceptScore W4251133741C31760486 @default.
- W4251133741 hasConceptScore W4251133741C502942594 @default.
- W4251133741 hasConceptScore W4251133741C526805850 @default.
- W4251133741 hasConceptScore W4251133741C535046627 @default.
- W4251133741 hasConceptScore W4251133741C55493867 @default.
- W4251133741 hasConceptScore W4251133741C62478195 @default.
- W4251133741 hasConceptScore W4251133741C71924100 @default.
- W4251133741 hasConceptScore W4251133741C86803240 @default.
- W4251133741 hasIssue "15_suppl" @default.
- W4251133741 hasLocation W42511337411 @default.
- W4251133741 hasOpenAccess W4251133741 @default.
- W4251133741 hasPrimaryLocation W42511337411 @default.
- W4251133741 hasRelatedWork W155879507 @default.
- W4251133741 hasRelatedWork W1977793218 @default.
- W4251133741 hasRelatedWork W2037724349 @default.
- W4251133741 hasRelatedWork W2050348440 @default.
- W4251133741 hasRelatedWork W2069668461 @default.
- W4251133741 hasRelatedWork W2086707902 @default.
- W4251133741 hasRelatedWork W2363674970 @default.
- W4251133741 hasRelatedWork W2521675697 @default.
- W4251133741 hasRelatedWork W2577979650 @default.
- W4251133741 hasRelatedWork W4310778869 @default.
- W4251133741 hasVolume "35" @default.
- W4251133741 isParatext "false" @default.
- W4251133741 isRetracted "false" @default.
- W4251133741 workType "article" @default.